The stock of Standard BioTools Inc (LAB) has seen a 0.93% increase in the past week, with a 3.81% gain in the past month, and a -7.63% decrease in the past quarter. The volatility ratio for the week is 6.30%, and the volatility levels for the past 30 days are at 5.32% for LAB. The simple moving average for the past 20 days is 4.26% for LAB’s stock, with a -28.62% simple moving average for the past 200 days.
Is It Worth Investing in Standard BioTools Inc (NASDAQ: LAB) Right Now?
The stock has a 36-month beta value of 1.50. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for LAB is 365.93M, and at present, short sellers hold a 4.66% of that float. On June 20, 2025, the average trading volume of LAB was 1.27M shares.
LAB) stock’s latest price update
The stock of Standard BioTools Inc (NASDAQ: LAB) has increased by 6.86 when compared to last closing price of 1.02. Despite this, the company has experienced a 0.93% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-30 that Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical development Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical development
Analysts’ Opinion of LAB
TD Cowen, on the other hand, stated in their research note that they expect to see LAB reach a price target of $3.50. The rating they have provided for LAB stocks is “Buy” according to the report published on April 16th, 2024.
Jefferies gave a rating of “Buy” to LAB, setting the target price at $3.25 in the report published on April 04th of the previous year.
LAB Trading at -0.56% from the 50-Day Moving Average
After a stumble in the market that brought LAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.77% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LAB starting from Kim Hanjoon Alex, who sale 1,428 shares at the price of $0.94 back on May 23 ’25. After this action, Kim Hanjoon Alex now owns 930,286 shares of Standard BioTools Inc, valued at $1,344 using the latest closing price.
Mackay Sean, the SVP & Chief Business Officer of Standard BioTools Inc, sale 13,217 shares at $0.94 during a trade that took place back on May 23 ’25, which means that Mackay Sean is holding 843,076 shares at $12,437 based on the most recent closing price.
Stock Fundamentals for LAB
Current profitability levels for the company are sitting at:
- -0.82 for the present operating margin
- 0.47 for the gross margin
The net margin for Standard BioTools Inc stands at -0.78. The total capital return value is set at -0.27. Equity return is now at value -25.73, with -19.56 for asset returns.
Based on Standard BioTools Inc (LAB), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -3.53. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -42.04.
Currently, EBITDA for the company is -118.14 million with net debt to EBITDA at 1.02. When we switch over and look at the enterprise to sales, we see a ratio of 1.74. The receivables turnover for the company is 4.78for trailing twelve months and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.12.
Conclusion
To sum up, Standard BioTools Inc (LAB) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
